search
Back to results

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

Primary Purpose

Renal Cell Cancer

Status
Terminated
Phase
Phase 3
Locations
Austria
Study Type
Interventional
Intervention
Capecitabine, Interferon, Interleukin
Sponsored by
Central European Cooperative Oncology Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Renal Cell Cancer focused on measuring renal cell cancer

Eligibility Criteria

19 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Histologically confirmed renal cell carcinoma (primary tumour or biopsy/surgery of metastases) Radiologically confirmed metastatic disease Surgically removed primary tumour so feasible (nephrectomy or nephron-sparing surgery as indicated) Karnofsky-Performance Status >70% Age 19-75 years Life expectancy of at least 3 months Adequate bone marrow function (i.e. white blood cell count above 3000/μL, platelet count above 75 000 /μL, hemoglobin above 9 mg/dl) Adequate organ function (i.e. serum creatinine, bilirubin and AST below 1.25 x the upper limit of the institutions' normal range) Negative pregnancy test for female patients Written informed consent Exclusion Criteria: Age <19 or >75 years Karnofsky-Performance Status < 70% Untreated or uncontrolled brain metastases Second neoplasia Primary tumour surgically removable Solitary, surgically removable metastases Major concomitant diseases of the cardiovascular, respiratory or renal systems, as well as active systemic infections Severe renal disease or liver insufficiency or myeloid dysfunction (including patients with a history of a disease that is likely to interfere with the metabolism or excretion of the test medication) Other less common diseases as peptic ulcer disease, inflammatory bowel disease, autoimmune disease (severe known psoriasis, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.) Drug addiction (including excessive alcohol consumption) within 1 year prior to study start. History of other conditions consistent with decompensated liver disease or other evidence of bleeding form esophageal varices. History of chronic hepatitis and immunsupressiva Known HIV Infection Evidence of allergy or hypersensitivity against recombinant Interferon alfa-2a or other components of preparation. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease. Seizure disorders and /or compromised central nervous system function. History of evidence of severe retinopathy Patient unwilling or unable to give informed consent Pregnancy or breastfeeding

Sites / Locations

  • Univ. Klinik f. Innere Medizin, Abt. Onkologie

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Capecitabine and Interferon

Interferon

Arm Description

Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy

Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine. Efficacy evaluations will be performed every 14 weeks of treatment in both groups

Outcomes

Primary Outcome Measures

The primary study objective is to investigate whether the addition of capecitabine to interferon-alpha-interleukin-2 based immunotherapy may improve progression free survival when compared to immunotherapy alone.

Secondary Outcome Measures

The study's secondary objectives are to investigate differences in response rates, safety and survival.

Full Information

First Posted
April 5, 2006
Last Updated
May 15, 2012
Sponsor
Central European Cooperative Oncology Group
search

1. Study Identification

Unique Protocol Identification Number
NCT00311467
Brief Title
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma
Official Title
Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma: a Prospective, Randomized, Multi-center phaseIII-Trial
Study Type
Interventional

2. Study Status

Record Verification Date
May 2012
Overall Recruitment Status
Terminated
Why Stopped
no patient recruitment
Study Start Date
March 2004 (undefined)
Primary Completion Date
May 2007 (Actual)
Study Completion Date
May 2007 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Central European Cooperative Oncology Group

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Multi-center, prospective randomised phase III study evaluating capecitabine in combination with standard-immunotherapy versus standard-immunotherapy alone as first-line therapy in patients with metastatic renal cell carcinoma.
Detailed Description
Treatment plan Group A Patients randomised to group A will receive treatment according to the following treatment schedule: Group A: Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy Week 1:Capecitabine / Interferon; Week 2:Capecitabine / Interferon; Week 3:REST PERIOD / Interleukin; Week 4:Capecitabine / Interleukin; Week 5:Capecitabine / REST PERIOD; Week 6:REST PERIOD / Interferon; Week 7:Capecitabine / Interferon; Week 8:Capecitabine / Interleukin; Week 9:REST PERIOD / Interleukin; Week 10:Capecitabine / REST PERIOD; Week 11:Capecitabine / Interferon; Week 12:REST PERIOD / Interferon; Week 13:Capecitabine / Interleukin; Week 14:Capecitabine / Interleukin; DOSAGES AND ROUTES OF ADMINISTRATION: Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days. Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d. Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day. Group B Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine. Efficacy evaluations will be performed every 14 weeks of treatment in both groups

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Renal Cell Cancer
Keywords
renal cell cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
172 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Capecitabine and Interferon
Arm Type
Active Comparator
Arm Description
Combined Chemo-Immunotherapy Chemotherapy: Mo-Fr Immunotherapy
Arm Title
Interferon
Arm Type
Active Comparator
Arm Description
Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine. Efficacy evaluations will be performed every 14 weeks of treatment in both groups
Intervention Type
Drug
Intervention Name(s)
Capecitabine, Interferon, Interleukin
Intervention Description
Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days. Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d. Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day. Group B Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine. Efficacy evaluations will be performed every 14 weeks of treatment in both groups
Primary Outcome Measure Information:
Title
The primary study objective is to investigate whether the addition of capecitabine to interferon-alpha-interleukin-2 based immunotherapy may improve progression free survival when compared to immunotherapy alone.
Secondary Outcome Measure Information:
Title
The study's secondary objectives are to investigate differences in response rates, safety and survival.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically confirmed renal cell carcinoma (primary tumour or biopsy/surgery of metastases) Radiologically confirmed metastatic disease Surgically removed primary tumour so feasible (nephrectomy or nephron-sparing surgery as indicated) Karnofsky-Performance Status >70% Age 19-75 years Life expectancy of at least 3 months Adequate bone marrow function (i.e. white blood cell count above 3000/μL, platelet count above 75 000 /μL, hemoglobin above 9 mg/dl) Adequate organ function (i.e. serum creatinine, bilirubin and AST below 1.25 x the upper limit of the institutions' normal range) Negative pregnancy test for female patients Written informed consent Exclusion Criteria: Age <19 or >75 years Karnofsky-Performance Status < 70% Untreated or uncontrolled brain metastases Second neoplasia Primary tumour surgically removable Solitary, surgically removable metastases Major concomitant diseases of the cardiovascular, respiratory or renal systems, as well as active systemic infections Severe renal disease or liver insufficiency or myeloid dysfunction (including patients with a history of a disease that is likely to interfere with the metabolism or excretion of the test medication) Other less common diseases as peptic ulcer disease, inflammatory bowel disease, autoimmune disease (severe known psoriasis, idiopathic thrombocytopenic purpura, lupus erythematosus, autoimmune hemolytic anemia, scleroderma, rheumatoid arthritis etc.) Drug addiction (including excessive alcohol consumption) within 1 year prior to study start. History of other conditions consistent with decompensated liver disease or other evidence of bleeding form esophageal varices. History of chronic hepatitis and immunsupressiva Known HIV Infection Evidence of allergy or hypersensitivity against recombinant Interferon alfa-2a or other components of preparation. History of severe psychiatric disease, especially depression. Severe psychiatric disease is defined as treatment with an antidepressant medication or a major tranquilizer at therapeutic doses for major depression or psychosis, respectively, for at least 3 months at any previous time or any history of the following: a suicidal attempt, hospitalization for psychiatric disease, or a period of disability due to a psychiatric disease. Seizure disorders and /or compromised central nervous system function. History of evidence of severe retinopathy Patient unwilling or unable to give informed consent Pregnancy or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manuela Schmidinger, Prof
Organizational Affiliation
Univ. Klinik f. Innere Med. I, Abt. Onkologie
Official's Role
Principal Investigator
Facility Information:
Facility Name
Univ. Klinik f. Innere Medizin, Abt. Onkologie
City
Vienna
ZIP/Postal Code
1090
Country
Austria

12. IPD Sharing Statement

Links:
URL
http://www.cecog.org
Description
Related Info

Learn more about this trial

Combined Treatment With Capecitabine and Immunotherapy Versus Immunotherapy Alone in Advanced Renal Cell Carcinoma

We'll reach out to this number within 24 hrs